Methods of inducing vasodilation

• US 20060079479A1
• Filed: 09/14/2005
• Published: 04/13/2006
• Est. Priority Date: 10/13/2004
• Status: Abandoned Application

• Current Assignee: Vanderbilt University
• Original Assignee: Vanderbilt University
• Inventors: Biaggioni, Italo
• Application Number:
  US11/226,626
• Publication Number:
  US 20060079479A1
• Time in Patent Office: Days
• US Class Current: 514/47
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid

Abstract

Provided herein are methods of inducing vasodilation in a subject diagnosed with a need for vasodilation, comprising administering into a blood vessel of the subject a therapeutically effective amount of a composition consisting essentially of adenosine monophosphate in a pharmaceutically acceptable carrier, whereby the administration of the composition induces vasodilation in the subject. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claims

1. A method of inducing vasodilation in a subject diagnosed with a need for vasodilation comprising administering into a blood vessel of the subject a therapeutically effective amount of a composition consisting essentially of adenosine monophosphate in a pharmaceutically acceptable carrier, whereby the administration of the composition induces vasodilation in the subject.

2. The method of claim 1, wherein the subject is not in need of anesthesia, analgesia, sedation, or iatrogenic hypothermia.

3. The method of claim 1, wherein the subject is not in need of treatment for stress or pathologic hypothermia.

4. The method of claim 1, wherein the subject is a mammal.

5. The method of claim 4, wherein the mammal is a human.

6. The method of claim 1, wherein the blood vessel is a venule or vein.

7. The method of claim 1, wherein the blood vessel is an arteriole or artery.

8. The method of claim 7, wherein the blood vessel is immediately proximate to a vascular bed.

9. The method of claim 8, wherein adenosine monophosphate is administered in a dosage of from about 5 μ

g to about 100 μ

g.

10. The method of claim 9, wherein adenosine monophosphate is administered in a dosage of about 30 μ

g.

11. The method of claim 1, wherein adenosine monophosphate is administered in a concentration of from about 0.05 mg/ml to about 400 mg/ml.

12. The method of claim 11, wherein adenosine monophosphate is administered in a concentration of from about 0.5 mg/ml to about 50 mg/ml.

13. The method of claim 12, wherein adenosine monophosphate is administered in a concentration of about 10 mg/ml.

14. The method of claim 1, wherein adenosine monophosphate is administered in a dosage of from about 10 μ

g per kg of bodyweight per minute to about 240 μ

g per kg of bodyweight per minute.

15. The method of claim 14, wherein adenosine monophosphate is administered in a dosage of about 180 μ

g per kg of bodyweight per minute.

16. The method of claim 1, wherein adenosine monophosphate is administered in a dosage of from about 1 mg to about 16 mg.

17. The method of claim 16, wherein adenosine monophosphate is administered in a dosage of about 8 mg.

18. The method of claim 1, wherein adenosine monophosphate is administered at a rate of from about 0.5 mg/minute to about 5 mg/minute.

19. The method of claim 18, wherein adenosine monophosphate is administered at a rate of about 3 mg/minute.

20. A method of inducing vasodilation in a human diagnosed with a need for vasodilation comprising administering into a blood vessel of the human a therapeutically effective amount of a composition consisting essentially of adenosine monophosphate in a pharmaceutically acceptable carrier, whereby the administration of the composition induces vasodilation in the human.

21. A method of inducing vasodilation in a subject diagnosed with a need for vasodilation comprising administering into a blood vessel of the subject a therapeutically effective amount of a composition consisting essentially of adenosine monophosphate in a pharmaceutically acceptable carrier, wherein the blood vessel is not a coronary artery, whereby the administration of the composition induces vasodilation in the subject.

22. A method of inducing vasodilation in a subject diagnosed with a need for vasodilation comprising administering into a blood vessel of the subject a therapeutically effective amount of a composition consisting essentially of adenosine and adenosine monophosphate in a pharmaceutically acceptable carrier, whereby the administration of the composition induces vasodilation in the subject.

23. A method of inducing vasodilation in a subject diagnosed with a need for vasodilation comprising administering into a blood vessel of the subject a therapeutically effective amount of a composition consisting essentially of adenosine monophosphate and lidocaine in a pharmaceutically acceptable carrier, whereby the administration of the composition induces vasodilation in the subject.